Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.34 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.34 |
| ▸ | CLK2 | P49760 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | CLK3 | P49761 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6649240 | 0.90 | KCNA5 (0.40) | HCRTR2HCRTR1RAB9AMGAT2NPC1 | |
| SCHEMBL6643972 | 0.84 | HCRTR2 (0.38) | HCRTR2HCRTR1RAB9AMGAT2CLK2 | |
| SCHEMBL6643944 | 0.83 | DGAT1 (0.32) | HTR2C | |
| SCHEMBL6649510 | 0.80 | HCRTR2 (0.42) | HCRTR2HCRTR1RAB9AMGAT2CLK2 | |
| SCHEMBL6645976 | 0.80 | TRPV4 (0.32) | — | |
| SCHEMBL6646519 | 0.77 | GAA (0.41) | RAB9ANPC1LMNA | |
| SCHEMBL6487835 | 0.76 | HTR2C (0.48) | RAB9ANPC1LMNAPKMHTR2A | |
| SCHEMBL6645551 | 0.74 | KMT2A (0.38) | LMNAPKMHTR2AHTR2C | |
| SCHEMBL6644677 | 0.73 | LMNA (0.43) | HCRTR2HCRTR1RAB9ACLK2DYRK1A | |
| SCHEMBL6648081 | 0.73 | TP53 (0.41) | RAB9AMGAT2NPC1LMNAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | HCRTR2 234/4885HCRTR1 314/4885RAB9A 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.